Last updated: May 26, 2026
DYANAVEL XR 5 (amphetamine) clinical trials update, market analysis, and projection
Executive summary: DYANAVEL XR 5 (amphetamine extended-release; NDA holder: Neos Therapeutics) is an established ADHD product with ongoing label refinement and periodic clinical activity focused on pediatric dosing, tolerability, and real-world positioning versus competing amphetamine and methylphenidate XR regimens. Market growth is expected to track US stimulant ADHD demand with share gains driven by prescriber switching to “once-daily” amphetamine XR options, payer step edits, and ongoing competitive pressure from other extended-release amphetamines, lisdexamfetamine formulations, and genericization risk in the broader stimulant class. Near-term revenue upside is constrained by category saturation, increasing payer restrictions, and periodic generic/or authorized generic availability across historical amphetamine XR SKUs.
What is DYANAVEL XR 5 and how is it positioned in US ADHD stimulant therapy?
DYANAVEL XR 5 is an extended-release amphetamine oral formulation used for attention-deficit/hyperactivity disorder (ADHD). It is marketed in the US as an amphetamine extended-release product, with pediatric dosing as a core commercial focus. The “5” refers to the 5 mg strength as a dosage availability within the extended-release range.
Therapeutic positioning (high-level):
- Category: central nervous system stimulant for ADHD.
- Delivery: extended-release oral dosing designed for once-daily coverage.
- Competitive set: extended-release amphetamine products and long-acting methylphenidate products, including branded and generic options depending on SKU and payer formularies.
Commercial relevance of extended-release amphetamine in ADHD:
- Prescriber preference trends toward once-daily regimens with consistent coverage and dosing flexibility.
- Payer contracting often favors cost-effective XR options and may impose step edits between branded amphetamine XR and branded or generic alternatives.
What clinical trials data exist for DYANAVEL XR (amphetamine) that inform dosing, safety, and label?
Primary evidence base is centered on ADHD efficacy and safety in pediatric patients, with attention to sustained symptom control over the school/workday and adverse event rates typical for stimulant therapies (appetite loss, insomnia, headache, abdominal pain, BP/HR effects).
Trial design patterns common to this product class (and typically applied to DYANAVEL XR):
- Randomized, controlled trials comparing DYANAVEL XR to placebo over defined titration and maintenance periods.
- Assessment using validated ADHD rating scales and functional endpoints.
- Safety monitoring for weight, vitals, insomnia, and appetite.
What clinicians and payers use as decision inputs:
- Magnitude and persistence of symptom control through the intended dosing interval.
- Tolerability profile in children and adolescents, especially appetite and sleep impacts.
- Label details affecting prescriber confidence in pediatric initiation and titration.
What is the latest clinical trials update for DYANAVEL XR 5 (study status, timelines, and endpoints)?
No complete, product-specific “DYANAVEL XR 5” trial listing with current recruitment status and readouts is available from the provided context. A clinical trials update in the strict sense requires either ClinicalTrials.gov identifiers for the exact product strength or specific sponsor-provided communications covering “DYANAVEL XR 5” as a distinct SKU. Without those, only class-level and product-level label-informed conclusions are possible.
Because a “complete and accurate response” is required, this section is not populated.
How strong is the patent and exclusivity protection for DYANAVEL XR 5, and when does exclusivity end?
A product-strength-specific patent map requires a confirmed Orange Book listing and corresponding patent family details (US patent numbers, application numbers, and expiration dates tied to the specific NDA strength/supplement). The required data is not present in the provided context.
Because a complete and accurate response is required, this section is not populated.
What is the Orange Book status of DYANAVEL XR 5 and are there paragraph IV filings?
Orange Book status, listed patents, and any paragraph IV challenges require direct access to FDA’s Orange Book record for the NDA and strength. The provided context contains no Orange Book dataset, no NDA number, and no patent listing.
Because a complete and accurate response is required, this section is not populated.
What generic entry risks exist for DYANAVEL XR 5 (ANDA timing and formulation/IP barriers)?
Generic entry risk for an extended-release amphetamine product hinges on:
- Orange Book patent expirations (listed drug and listed formulation/method patents),
- FDA approval pathway constraints (including 505(b)(2) vs ANDA mechanics),
- Orange Book-triggered litigation and any settlement.
None of these inputs are available in the provided context.
Because a complete and accurate response is required, this section is not populated.
What patent litigation affects DYANAVEL XR, including settlement agreements and how it impacts launch timing?
Patent litigation status requires:
- case captions, filing dates, and district courts,
- specific asserted patents and whether cases settled or went to judgment,
- any consent decrees or stipulations that govern “at-risk” launch.
The provided context includes no litigation record.
Because a complete and accurate response is required, this section is not populated.
How does DYANAVEL XR 5 compare with competing ADHD stimulants on efficacy, dosing convenience, and safety?
Competitive comparison is typically driven by:
- Dosing convenience: once-daily extended-release versus multiple daily dosing options.
- Dosing flexibility: available strengths and titration ease.
- Tolerability: appetite suppression, insomnia, and cardiovascular monitoring burdens.
- Payer preference: formulary position and PBM rebates.
Practical competitive dynamics in the stimulant class:
- “Switching” behavior is common when payers prefer lower net cost.
- Clinicians may remain stable if a patient has good response and tolerability on an established regimen.
Because drug-level comparative outcomes for DYANAVEL XR 5 require head-to-head or indirect comparison sources not provided here, this section is restricted to decision-factors rather than quantified comparative performance.
What is the market size for US ADHD stimulants, and where does DYANAVEL XR 5 fit in the forecast?
Category growth drivers:
- Persistent ADHD diagnosis prevalence in children and adults.
- Continued adoption of extended-release once-daily regimens.
- Ongoing payer and provider demand for predictable coverage and tolerability.
Category headwinds:
- Competitive intensity across amphetamine XR and methylphenidate XR portfolios.
- Payer formulary restrictions, step therapy, and increasing emphasis on cost-effectiveness.
- Regulatory and public-policy scrutiny on stimulant prescribing and supply controls.
Forecast logic for DYANAVEL XR 5 (how projection is typically constructed):
- Start with stimulant ADHD market trajectory in the US.
- Apply share assumptions based on formulary access, net pricing (post-rebate), and switching dynamics from competing branded XR products.
- Apply risk adjustments for genericization or authorized generic pressures within the amphetamine XR segment.
- Segment by pediatric vs adolescent demand where dosing flexibility matters most.
No numeric market size, share, or pricing inputs are available in the provided context, so a quantified forecast cannot be produced without breaching the “complete and accurate” constraint.
Because a complete and accurate response is required, this section is not populated.
DYANAVEL XR 5 US revenue projection: base case, bull case, bear case
A credible revenue projection requires at minimum:
- current US sales by year or at least a baseline unit and net price,
- formulary penetration and competitive share,
- expected payer and genericization timeline impacts,
- geographic scope and channel mix (retail vs mail).
The provided context contains none of these.
Because a complete and accurate response is required, this section is not populated.
Which stakeholders should monitor for DYANAVEL XR 5 market shifts (FDA, payers, and competitors)?
Even without quantified forecasts, the market can shift materially when any of the following changes:
- FDA label changes that expand or constrain pediatric dosing.
- PBM formulary changes or rebate renegotiations that alter net cost competitiveness.
- Competitor launch events for newer XR amphetamine formulations or reformulations.
- Supply constraints or compliance actions impacting stimulant availability.
- Generic entry in overlapping amphetamine XR indications where interchangeability affects share.
This is the correct monitoring framework; however, specific “what happened” dates and events for DYANAVEL XR 5 are not provided.
Key Takeaways
- DYANAVEL XR 5 is a US marketed extended-release amphetamine ADHD product, with commercial positioning dependent on once-daily coverage and pediatric tolerability.
- A strict “clinical trials update” for the exact “DYANAVEL XR 5” strength and a quantified revenue projection require specific trial identifiers and sales/market inputs that are not present in the provided context.
- Market outcomes in this therapeutic category are primarily driven by formulary access, net pricing, and genericization/authorized generic dynamics.
FAQs
- What FDA label elements most affect prescribing for DYANAVEL XR extended-release amphetamine in pediatric ADHD?
- How do PBM step edits typically influence switching between amphetamine XR products and methylphenidate XR products?
- What are the main safety monitoring parameters used for stimulant ADHD therapies and how do they impact persistence?
- How does generic entry pressure usually propagate across the amphetamine XR segment in ADHD?
- What should be tracked to anticipate changes in ADHD stimulant demand (diagnosis, persistence, and payer access)?
References
No sources were cited because the required product-specific clinical, Orange Book, exclusivity, litigation, and market data were not provided in the prompt.
